StreetInsider.com News Articles

MIRA Pharmaceuticals expands Ketamir-2 licensing to worldwide rights

Wed, 27 May 2026 08:00:59 -0400

MIRA Pharmaceuticals Inc. (NASDAQ:MIRA) announced it has amended its licensing agreement with MIRALOGX LLC to expand rights for its drug candidate Ketamir-2 from North American markets to worldwide coverage.

The amended agreement extends the company's licensed territory from the United States, Canada, and Mexico to include all countries where patent rights exist. The international patent portfolio now covers filings in the United States, Europe, China, Japan, Canada, Australia, India, Israel, Mexico, and South Korea.

Ketamir-2 is an oral NMDA receptor modulator that MIRA is developing for chemotherapy-induced peripheral neuropathy. The company recently completed Phase 1 clinical trials involving 56 healthy volunteers, reporting

Form 8-K MIRA PHARMACEUTICALS, For: May 21

Wed, 27 May 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260527/26553824.html

Form 8-K MIRA PHARMACEUTICALS, For: May 21

Wed, 27 May 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260527/26553824.html

MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN

Wed, 27 May 2026 08:00:00 -0400

Expanded Global Intellectual Property Portfolio Enhances Strategic Flexibility and Long-Term Value Potential for Ketamir-2

MIAMI, FL / ACCESS Newswire / May 27, 2026 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company focused on the development of proprietary therapeutics for neurologic, neuropsychiatric, inflammatory, and metabolic disorders, today announced the execution of Amendment No. 1 to its exclusive Ketamir-2 license agreement with MIRALOGX LLC, expanding the Company's licensed territory from the United States, Canada, and Mexico to worldwide rights across all countries in which patent rights exist.

The amended agreement

MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN

Wed, 27 May 2026 08:00:00 -0400

Expanded Global Intellectual Property Portfolio Enhances Strategic Flexibility and Long-Term Value Potential for Ketamir-2

The amended agreement

Form 10-Q MIRA PHARMACEUTICALS, For: Mar 31

Thu, 14 May 2026 15:04:00 -0400

si-local-file:///var/storage/secattach/20260514/26493907.html

Form 10-Q MIRA PHARMACEUTICALS, For: Mar 31

Thu, 14 May 2026 15:04:00 -0400

si-local-file:///var/storage/secattach/20260514/26493907.html

MIRA Pharmaceuticals reports positive Phase 1 results for Ketamir-2

Thu, 14 May 2026 08:01:04 -0400

MIRA Pharmaceuticals Inc. (NASDAQ: MIRA) announced positive results from its completed Phase 1 clinical trial evaluating Ketamir-2, an oral NMDA receptor modulator, according to a company statement.

The randomized, double-blind, placebo-controlled study evaluated safety, tolerability, and pharmacokinetics of Ketamir-2 in 57 healthy volunteers across seven cohorts. All participants completed the study with no withdrawals.

The trial reported no serious adverse events or dose-limiting toxicities. Adverse events were predominantly mild, with higher incidence in the placebo group compared to the Ketamir-2 group. Pharmacokinetic analysis showed rapid oral absorption and dose-proportional maximum concentration across evaluated doses.

Ketamir-2 demonstrated a half-life of approximately 2.5 to 7

MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2

Thu, 14 May 2026 08:00:00 -0400

Selective oral NMDA receptor modulator demonstrated favorable safety, tolerability, and pharmacokinetic profile supporting planned Phase 2a development in chemotherapy-induced peripheral neuropathy

MIAMI, FL / ACCESS Newswire / May 14, 2026 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), today announced positive unblinded results from its completed Phase 1 clinical trial evaluating Ketamir-2, the Company's proprietary selective oral NMDA receptor modulator.

The randomized, double-blind, placebo-controlled Phase 1 study evaluated the safety, tolerability, and pharmacokinetics of orally administered Ketamir-2 in healthy volunteers across single ascending dose (SAD) and multiple ascending dose (MAD) cohorts.

A total

MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2

Thu, 14 May 2026 08:00:00 -0400

A total

Form 8-K MIRA PHARMACEUTICALS, For: May 13

Wed, 13 May 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260513/26485703.html

Form 8-K MIRA PHARMACEUTICALS, For: May 13

Wed, 13 May 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260513/26485703.html

MIRA Pharmaceuticals publishes peer-reviewed study on obesity drug candidate

Wed, 13 May 2026 08:04:07 -0400

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) announced the publication of a peer-reviewed manuscript describing preclinical findings for SKNY-1, its oral investigational drug candidate for obesity and nicotine addiction, in the International Journal of Molecular Sciences.

The study, conducted in an MC4R-deficient zebrafish model, demonstrated that SKNY-1 produced dose-dependent weight reduction, with the higher dose group showing approximately 30% reduction relative to baseline after six days of oral administration. The compound also reduced total cholesterol, low-density lipoprotein, and hepatic triglyceride accumulation compared to untreated controls.

According to the publication, SKNY-1 demonstrated differential engagement of cannabinoid receptor 1 signaling pathways, partial agonist activity at cannabinoid receptor

MIRA Pharmaceuticals Announces Acceptance of Peer-Reviewed SKNY-1 Manuscript Highlighting Oral Obesity and Nicotine Addiction Drug Candidate

Wed, 13 May 2026 08:00:00 -0400

Peer-reviewed publication highlights preclinical findings demonstrating weight loss, lipid normalization, and reduction of compulsive feeding and nicotine-seeking behaviors

MIAMI, FL / ACCESS Newswire / May 13, 2026 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company focused on the development of investigational therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced the acceptance and publication of a peer-reviewed manuscript describing the preclinical pharmacology and activity of SKNY-1, the Company's oral investigational drug candidate being evaluated for obesity and nicotine addiction, in the International Journal of Molecular Sciences.

The publication,

MIRA Pharmaceuticals Announces Acceptance of Peer-Reviewed SKNY-1 Manuscript Highlighting Oral Obesity and Nicotine Addiction Drug Candidate

Wed, 13 May 2026 08:00:00 -0400

Peer-reviewed publication highlights preclinical findings demonstrating weight loss, lipid normalization, and reduction of compulsive feeding and nicotine-seeking behaviors

The publication,

Form 8-K MIRA PHARMACEUTICALS, For: May 12

Wed, 13 May 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260513/26481758.html

Form 8-K MIRA PHARMACEUTICALS, For: May 12

Wed, 13 May 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260513/26481758.html

Form 4 MIRA PHARMACEUTICALS, For: Mar 30 Filed by: Aminov Erez

Wed, 01 Apr 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260401/26260238.html

Form 4 MIRA PHARMACEUTICALS, For: Mar 30 Filed by: Aminov Erez

Wed, 01 Apr 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260401/26260238.html

Form 10-K MIRA PHARMACEUTICALS, For: Dec 31

Tue, 31 Mar 2026 14:03:00 -0400

si-local-file:///var/storage/secattach/20260331/26249620.html

Form 10-K MIRA PHARMACEUTICALS, For: Dec 31

Tue, 31 Mar 2026 14:03:00 -0400

si-local-file:///var/storage/secattach/20260331/26249620.html

MIRA Pharmaceuticals reports Mira-55 shows no CNS side effects in studies

Mon, 23 Mar 2026 09:03:54 -0400

MIRA Pharmaceuticals Inc. (NASDAQ: MIRA) announced preclinical data showing its drug candidate Mira-55 did not produce central nervous system side effects associated with cannabis compounds or certain cannabinoid receptor antagonists.

The study, conducted with Pharmaseed, tested Mira-55 at oral doses of 10, 30, and 100 mg/kg using behavioral assays including hypothermia, catalepsy, elevated plus maze, and open field tests. The compound showed no psychogenic effects, sedation, catalepsy, or motor impairment at any tested dose.

In elevated plus maze testing, Mira-55 demonstrated a dose-dependent increase in time spent in open arms, indicating reduced anxiety-like behavior. Open field testing showed Mira-55-treated groups performed comparably

MIRA Pharmaceuticals reports Mira-55 shows no CNS side effects in studies

Mon, 23 Mar 2026 09:03:54 -0400

Form 8-K MIRA PHARMACEUTICALS, For: Mar 23

Mon, 23 Mar 2026 09:01:00 -0400

si-local-file:///var/storage/secattach/20260323/26201446.html

Form 8-K MIRA PHARMACEUTICALS, For: Mar 23

Mon, 23 Mar 2026 09:01:00 -0400

si-local-file:///var/storage/secattach/20260323/26201446.html